In an interview published on OncLive, Michael J. Morris, MD, discusses the results of the CONDOR trial and the utility of PSMA-targeted PET imaging in prostate cancer.
The prostate specific membrane antigen (PSMA)-targeted PET radiopharmaceutical 18F-DCFPyL-PET/CT identified localized disease that went undetected with standard imaging in men with biochemically recurrent prostate cancer, according to results from the phase 3 CONDOR trial, explained Michael J. Morris, MD, who added that the modality also impacted subsequent treatment decisions.
To be eligible for enrollment, men had to have biochemically relapsed prostate cancer defined by a prostate-specific antigen (PSA) level of at least 0.2 ng/mL if they had undergone radical prostatectomy or at least 2 ng/mL if they had radiation therapy or cryotherapy, as well as negative or equivocal standard-of-care imaging.
In total, 208 men received the 18F-DCFPyL tracer. The correct localization rate (CLR) of true positives among 3 independent readers ranged from 84.8% (95% CI, 77.8%-91.9%) to 85.6% (95% CI, 78.8%-92.3%) to 87.0% (95% CI, 80.4-93.6%), superseding the predefined 20% CLR for success.
Moreover, 63.9% of patients had a change in their intended treatment course after receiving the 18F-DCFPyL tracer.
“These data show that the positive predictive value of PyL is very good. Secondly, clinicians trust the scan and act on it. They believe that the information that’s furnished by the scan is actionable enough to change the goal of treatment, if not the treatment itself,” said Morris.
Read more from OncLive.